Giant Industries, Inc.
GI
New York Stock Exchange8.00
USD
- -
- -
CIK
0000856465
CUSIP
374508109
Return %
Stock
S&P500
1Y
- -
19.01
3Y
- -
65.49
5Y
- -
72.21
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Energy
- Industry
- Oil & Gas Refining & Marketing
- Address
- IPO Date
- Jun 4, 2015
- CIK
- 0000856465
- Similar Companies
- Business
- Giant Industries, Inc. (GI) manufactures and distributes high-pressure pumps, accessories, and custom systems for industrial applications including pressure washing, car washes, sewer cleaning, oilfield services, carpet cleaning, steel mills, reverse osmosis, and agriculture. The company offers American-made triplex plunger pumps such as the GX, P200, and P300 series with flow rates from 3.4 GPM to 132 GPM and pressures up to 15,000 PSI, alongside German-engineered Kamat pumps reaching up to 50,750 PSI and 2,000 HP; it also provides a complete range of accessories like shut-off guns, rotating nozzles, surface cleaners, hoses, fittings, valves, and remotely operated units, plus towels and trailer- or skid-mounted waterjetting systems with optional sound-proof enclosures. Founded in 1972 by Ray Simon as the Giant Towel Company in Toledo, Ohio, where it remains headquartered, Giant Industries serves customers across North, South, and Central America through its facilities equipped for machining, production, and assembly. In recent years, the company celebrated its 50th anniversary in 2022 by highlighting expansions into heavy-duty markets and introduced the HPUDT-235 Series quiet power unit rated at 8 GPM and 40,000 PSI ahead of the 2025 WJTA Expo, reinforcing its commitment to innovative, high-reliability solutions amid ongoing demand for custom high-pressure systems.
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
Alight Adds Cylinder and Leap to Partner Network